Ng George K 4/A

What Happened
George K. Ng, CEO of Processa Pharmaceuticals, bought 1,843 shares of Processa common stock in an open-market purchase on April 15, 2026, at $2.97 per share for a total cost of approximately $5,474. The Form 4 was filed as an amended report on April 30, 2026.

Key Details

• Transaction date and price: 2026-04-15 — Purchase (code P) of 1,843 shares at $2.97 each.
• Total value: ≈ $5,474.
• Filing: Amended Form 4 filed 2026-04-30 (transaction was reported late — transactionTimeliness = 'L').
• Shares owned after transaction: Not specified in the amended filing.
• Footnotes/notable disclosures: No 10b5-1 plan, tax withholding, or other special footnotes disclosed in the provided filing details.

Context
This was a straightforward open-market purchase by the CEO. Purchases by insiders are often viewed as a more informative signal than sales, though this is a relatively small-dollar purchase. The amended and late filing means public disclosure was delayed, which can reduce the timeliness of the information for investors.